Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 13/20 | 0.44 |
| ▸ | CEPT1 | Q9Y6K0 | 5/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787642 | 0.88 | CETP (0.55) | CETPCEPT1ESR1ESR2 | |
| SCHEMBL3685017 | 0.82 | CETP (0.50) | CETPCEPT1ESR2 | |
| SCHEMBL1733972 | 0.81 | CEPT1 (0.53) | CETPCEPT1 | |
| SCHEMBL1735106 | 0.78 | CETP (0.54) | CETPCEPT1ESR1ESR2 | |
| SCHEMBL3681612 | 0.76 | ESR2 (0.55) | CETPCEPT1ESR1ESR2 | |
| SCHEMBL3792093 | 0.74 | ESR2 (0.60) | CETPCEPT1ESR1ESR2 | |
| SCHEMBL18593334 | 0.72 | NPC1 (0.43) | CETPCEPT1ESR1ESR2 | |
| SCHEMBL30368400 | 0.72 | KIF11 (0.45) | CETPCEPT1ESR1ESR2 | |
| SCHEMBL1733840 | 0.71 | HDAC6 (0.60) | CETPESR1ESR2 | |
| SCHEMBL1733969 | 0.71 | ESR2 (0.51) | CETPCEPT1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170058-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8445480-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | CETP 1/4885CEPT1 195/4885ESR1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.